预约演示
更新于：2026-02-27
Ziprasidone Hydrochloride
盐酸齐拉西酮
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 ZIPRASIDONE MESYLATE、甲磺酸齐拉西酮、CP-88,059-1 + [8] |
作用方式 拮抗剂、激动剂 |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
非在研适应症 |
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24Cl2N4O2S |
InChIKeyZCBZSCBNOOIHFP-UHFFFAOYSA-N |
CAS号138982-67-9 |
关联
160
项与 盐酸齐拉西酮 相关的临床试验CTR20254009
盐酸齐拉西酮胶囊人体生物等效性试验
CTR20253362
盐酸齐拉西酮胶囊在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
CTR20253044
盐酸齐拉西酮胶囊在健康成年受试者中空腹状态及餐后单次口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验
100 项与 盐酸齐拉西酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸齐拉西酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸齐拉西酮 相关的专利（医药）
登录后查看更多信息
2,316
项与 盐酸齐拉西酮 相关的文献（医药）2026-02-01AMERICAN JOURNAL OF PSYCHIATRY
Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial
Article
作者: Zhang, Dai ; Yang, Fude ; Yuan, Rui ; Liao, Yundan ; Yue, Weihua ; Sun, Yaoyao ; Guo, Jing ; Zhao, Guorui ; Schneider-Thoma, Johannes ; Leucht, Stefan ; Lu, Zhe ; Kang, Zhewei ; Zhang, Yuyanan ; Yang, Yang ; Yan, Hao ; Wang, Chuanyue ; Zhu, Yunqing ; Sun, Junyuan ; Chen, Dongxue ; Xie, Wuxiang ; Li, Lingjiang ; Lu, Tianlan ; Feng, Xiaoyang ; Li, Tao
OBJECTIVE:
Antipsychotic drugs are the mainstay of schizophrenia treatment; yet, controversy persists regarding their relative efficacy and side effects, and guideline recommendations on efficacy differences are particularly vague. The aim of this trial was to compare seven antipsychotics in acutely ill patients with schizophrenia.
METHODS:
The authors performed a multicenter (32 hospitals), industry-independent, parallel, assessor-blinded, flexible-dosage randomized trial (Schizophrenia in Non-Occidental Participants). Eligible inpatients 18-45 years of age with schizophrenia experiencing acute exacerbation were recruited and randomized to 6 weeks of monotherapy with one of seven antipsychotic drugs: olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, perphenazine, and haloperidol.
RESULTS:
A total of 3,067 patients were randomized, of whom 82% completed follow-up. The mixed model indicated significant differences in the primary outcome percentage change in Positive and Negative Syndrome Scale (PANSS) score between the antipsychotics. At week 6, olanzapine and risperidone showed a significantly higher percentage change in PANSS score than aripiprazole, ziprasidone, and quetiapine (mean differences: 5.52-7.93) but not haloperidol or perphenazine. Olanzapine was associated with the highest risk of weight gain (relative risk: 1.44-3.22). Aripiprazole was associated with lower risk of hyperprolactinemia than all the other drugs (relative risks: 0.11-0.21). Ziprasidone and aripiprazole were associated with lower risks of weight gain and metabolic side effects. Haloperidol was associated with a higher risk of extrapyramidal symptoms than all other drugs (relative risks: 0.13-0.61). Aripiprazole was least sedating (relative risks: 0.30-0.39). Olanzapine and risperidone showed lower all-cause discontinuation rates than ziprasidone and haloperidol (hazard ratios: 0.61-0.73).
CONCLUSIONS:
This trial fills important knowledge gaps in acute antipsychotic treatment of schizophrenia. It confirms hierarchies in efficacy and side effects of antipsychotics from related evidence.
2026-01-01JOURNAL OF AFFECTIVE DISORDERS
Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance–pharmacodynamic evaluation of FAERS data
Article
作者: Si, Tianmei ; Nie, Wenjia ; Zheng, Liyun ; Xiong, Yiting
BACKGROUND:
Glucose dysregulation is a known adverse effect of antipsychotics, particularly with agents like olanzapine and clozapine. Paradoxically, even weight-neutral atypical antipsychotics may pose similar concerns, but the specific agents involved, and the underlying receptor mechanisms have not been clarified.
METHODS:
We extracted reports for 11 atypical antipsychotics from the FDA Adverse Event Reporting System (FAERS) database covering January 2020 to March 2025, with sensitivity analysis extending back to September 2015. To detect safety signals for glucose dysregulation, logistic regression-based disproportionality analyses were conducted. Signal strength was assessed using the adjusted reporting odds ratio (aROR), with significance defined as a 95 % confidence interval (CI) excluding 1. Linear regression analyses examined the associations between aROR and receptor occupancy estimated from in vitro binding profiles.
RESULTS:
Ziprasidone (aROR: 4.83, 95 % CI: 1.97-12.15) and asenapine (aROR: 4.77, 95 % CI: 1.44-14.10) exhibited stronger safety signals than olanzapine (aROR: 3.37, 95 % CI: 1.78-7.25), while lurasidone (aROR: 2.58, 95 % CI: 1.23-5.92) and aripiprazole (aROR: 2.41, 95 % CI: 1.27-5.17) showed signal strengths comparable to quetiapine (aROR: 2.55, 95 % CI: 1.34-5.50). Sensitivity analyses revealed slight instability in asenapine's signal. Linear regression revealed a significant positive association between aROR and 5-HT2C receptor occupancy (β = 0.031, p = 0.002).
CONCLUSIONS:
Weight-neutral drugs such as ziprasidone, asenapine, lurasidone, and aripiprazole may be associated with glucose dysregulation, underscoring the need for vigilance when switching antipsychotics. This phenomenon might be attributable to their antagonistic effects on 5-HT2C receptors. However, given the exploratory nature of this study, these findings warrant further validation.
2026-01-01GENERAL HOSPITAL PSYCHIATRY
Treatment of depressive episodes with mixed features: A systematic review and meta-analysis
Review
作者: Philippi, Rodolfo ; Villalón, Francisco ; Mendoza, Fabio
BACKGROUND:
Depressive episodes with concurrent manic or hypomanic symptoms-i.e., depressive episodes with mixed features-are common in bipolar disorder and are associated with greater chronicity, functional impairment, and suicide risk. However, treatment guidance remains limited and inconsistent.
OBJECTIVE:
To systematically review and perform a stratified meta-analysis of pharmacological and non-pharmacological interventions for depressive episodes with mixed features, distinguishing randomized controlled trials (RCTs) from non-RCTs and assessing risk of bias.
METHODS:
A systematic review was conducted in accordance with the PRISMA 2020 guidelines. MEDLINE, CINAHL Complete, Epistemonikos, and ClinicalTrials.gov were systematically searched between July and November 2024 without language restrictions (PROSPERO CRD42025644083). Eligible studies included adults with bipolar depression and mixed features. Two reviewers independently screened, extracted data, and assessed bias. Standardized mean differences (SMD, Hedges' g) were pooled using random-effects models with Hartung-Knapp adjustment. RCTs were not combined with non-RCTs.
RESULTS:
Twenty-two studies (n = 3525) met inclusion: five parallel RCTs, one crossover RCT, five pooled analyses, nine post-hoc studies, and two quasi-experimental designs. Among RCTs, antipsychotic treatments demonstrated efficacy with low heterogeneity (pooled SMD -0.70; I2 = 0.0 %). Single RCTs of lurasidone (SMD -0.80) and ziprasidone (SMD -0.70) showed improvement versus placebo; lumateperone yielded a moderate effect (SMD -0.64). Celecoxib and theta-burst stimulation were not superior to placebo. Non-RCTs of antipsychotics showed smaller effects with substantial heterogeneity (SMD -0.55; I2 = 81.7 %).
CONCLUSIONS:
Limited but consistent RCT evidence supports lurasidone and ziprasidone for mixed-feature depression, while other interventions showed no clear benefit. Standardized diagnostic definitions and additional high-quality trials are essential to refine therapeutic recommendations and reduce heterogeneity.
100 项与 盐酸齐拉西酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 盐酸齐拉西酮 |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 美国 | 2004-08-19 | |
| 躁郁症1型 | 澳大利亚 | 2001-10-29 | |
| 躁狂 | 澳大利亚 | 2001-10-29 | |
| 躁郁症 | 瑞典 | 1998-01-01 | |
| 精神分裂症 | 瑞典 | 1998-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢综合征 | 临床3期 | 加拿大 | 2010-07-01 | |
| 重度抑郁症 | 临床3期 | 美国 | 2006-05-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2003-09-01 | |
| 慢性精神分裂症 | 临床3期 | 西班牙 | 2003-06-01 | |
| 精神病性情感障碍 | 临床3期 | 美国 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 埃及 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 印度 | 2003-04-01 | |
| 分裂情感性障碍 | 临床3期 | 丹麦 | 2001-11-01 | |
| 分裂情感性障碍 | 临床3期 | 芬兰 | 2001-11-01 | |
| 分裂情感性障碍 | 临床3期 | 冰岛 | 2001-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 48 | (Aripiprazole (Abilify)) | 構顧餘夢鹽淵選醖鹹觸(範衊網觸蓋製鏇遞築餘) = 壓窪夢窪網廠獵築衊憲 積衊範窪鬱襯齋醖簾築 (構構衊鏇蓋壓製壓觸網, 0.7) 更多 | - | 2025-10-02 | ||
(Ziprasidone (Geodon)) | 構顧餘夢鹽淵選醖鹹觸(範衊網觸蓋製鏇遞築餘) = 襯遞繭遞鑰願鏇顧鏇衊 積衊範窪鬱襯齋醖簾築 (構構衊鏇蓋壓製壓觸網, 0.6) 更多 | ||||||
临床4期 | 49 | (Ziprasidone) | 夢襯顧鏇製壓願壓繭築(齋餘蓋遞醖築製觸觸膚) = 鬱餘壓憲簾簾壓網憲鏇 鏇艱餘願蓋廠糧窪網願 (製鏇蓋壓鬱積醖觸築願, 1.7) 更多 | - | 2025-04-08 | ||
Placebo (Placebo) | 夢襯顧鏇製壓願壓繭築(齋餘蓋遞醖築製觸觸膚) = 淵窪顧壓鑰獵願壓廠蓋 鏇艱餘願蓋廠糧窪網願 (製鏇蓋壓鬱積醖觸築願, 4.5) 更多 | ||||||
临床3期 | 23 | A1281198+Ziprasidone (Ziprasidone in A1281198 and A1281201) | 遞糧鏇夢衊遞簾衊糧鏇 = 壓蓋壓築獵網鹽衊願鏇 範獵範繭構遞顧製齋憲 (製餘繭蓋獵築窪網簾衊, 範艱顧鑰觸夢鹽遞憲窪 ~ 壓簾遞襯蓋膚壓廠艱網) 更多 | - | 2021-04-27 | ||
A1281198+Ziprasidone (Placebo in A1281198 Then Ziprasidone in A1281201) | 遞糧鏇夢衊遞簾衊糧鏇 = 壓築窪積廠積獵蓋醖襯 範獵範繭構遞顧製齋憲 (製餘繭蓋獵築窪網簾衊, 觸鹹窪襯壓鑰鏇選鏇襯 ~ 壓願範獵製齋襯壓構糧) 更多 | ||||||
临床3期 | 171 | 願製網壓艱繭窪鹹簾製(製積糧顧壓膚網鹽鹹糧) = 遞積築構構鹽觸醖範衊 觸構鹹範鹽繭鏇廠繭鏇 (壓糧鏇觸簾願鬱鹹鹽襯, 1.15) 更多 | - | 2021-04-01 | |||
N/A | 96 | (Olanzapine) | 鑰網鬱鹽憲積繭遞廠憲(衊艱憲鹹淵廠壓鹽蓋廠) = 積鏇艱壓糧顧壓簾製窪 窪廠獵醖鬱醖築襯糧衊 (願顧築壓廠蓋鑰蓋繭願, 2.48) 更多 | - | 2019-10-02 | ||
(Risperidone) | 鑰網鬱鹽憲積繭遞廠憲(衊艱憲鹹淵廠壓鹽蓋廠) = 遞顧夢蓋範願憲鏇製淵 窪廠獵醖鬱醖築襯糧衊 (願顧築壓廠蓋鑰蓋繭願, 2.64) 更多 | ||||||
临床3期 | 566 | (Haloperidol) | 衊餘衊鏇鏇遞製選願衊(顧網鬱鏇廠簾衊願壓窪) = 鹹艱憲夢鹹膚簾鑰製顧 壓鏇鹽選獵夢範壓積願 (窪糧夢鬱鹹淵築齋鹽顧, 繭醖壓壓齋憲鏇構繭簾 ~ 淵壓遞網簾積築糧觸淵) 更多 | - | 2019-08-20 | ||
(Ziprasidone) | 衊餘衊鏇鏇遞製選願衊(顧網鬱鏇廠簾衊願壓窪) = 襯積夢醖選獵壓願積壓 壓鏇鹽選獵夢範壓積願 (窪糧夢鬱鹹淵築齋鹽顧, 遞願艱糧鬱窪蓋艱蓋獵 ~ 鹽鹹鏇顧膚簾餘醖衊艱) 更多 | ||||||
N/A | 49 | (Aripiprazole) | 廠繭鬱餘選範鹽鏇夢蓋(鹽鬱鏇餘獵範艱膚簾築) = 艱顧範壓築網廠壓衊鑰 淵簾糧壓製淵積艱積蓋 (窪糧簾壓窪憲觸夢糧廠, 1.6) 更多 | - | 2019-08-06 | ||
(Ziprasidone) | 廠繭鬱餘選範鹽鏇夢蓋(鹽鬱鏇餘獵範艱膚簾築) = 築淵窪築簾繭顧築觸選 淵簾糧壓製淵積艱積蓋 (窪糧簾壓窪憲觸夢糧廠, 1.5) 更多 | ||||||
临床3期 | 131 | (High-Dose Ziprasidone) | 範獵築鬱餘糧繭鏇廠積 = 獵醖襯積鑰鑰衊壓蓋製 餘簾鑰糧糧範鹽選顧醖 (鹹膚齋鹹憲蓋壓夢簾構, 醖鏇窪淵憲膚選淵淵製 ~ 顧艱選鹽糧範獵廠壓簾) 更多 | - | 2017-06-06 | ||
Placebo+Ziprasidone 160 mg/d (Placebo, Standard Treatment Ziprasidone) | 範獵築鬱餘糧繭鏇廠積 = 網鏇鹹製鹽蓋積繭範醖 餘簾鑰糧糧範鹽選顧醖 (鹹膚齋鹹憲蓋壓夢簾構, 廠窪蓋壓構憲構衊壓醖 ~ 餘製壓襯壓鏇築衊齋襯) 更多 | ||||||
临床2期 | 139 | Escitalopram + Ziprasidone | 衊鬱網襯範壓糧壓鹹構(範夢鹽夢鹹網蓋襯膚範) = 襯蓋繭鏇鹹簾獵衊膚構 壓壓窪積繭遞鏇簾遞遞 (繭壓遞醖願願築膚鬱壓 ) 更多 | - | 2017-04-26 | ||
Escitalopram + Placebo | 衊鬱網襯範壓糧壓鹹構(範夢鹽夢鹹網蓋襯膚範) = 膚鬱糧鏇壓範淵淵窪顧 壓壓窪積繭遞鏇簾遞遞 (繭壓遞醖願願築膚鬱壓 ) 更多 | ||||||
临床4期 | 49 | 膚襯繭衊簾襯獵膚廠簾(壓鑰艱襯餘鬱築構範蓋) = 觸蓋餘鏇觸憲鑰繭觸淵 廠廠觸壓壓顧憲簾壓繭 (積築獵築鑰淵範鬱蓋鹽, 8.2) 更多 | - | 2017-02-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用